echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > The National Institute for Health and Clinical Excellence recommends Baiyueze? (Zebutinib) is used to treat patients with Fahrenheit macroglobulinemia who have previously received at least one treatment

    The National Institute for Health and Clinical Excellence recommends Baiyueze? (Zebutinib) is used to treat patients with Fahrenheit macroglobulinemia who have previously received at least one treatment

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    BeiGene has announced that the UK's National Institute for Health and Clinical Excellence (NICE), the UK's health technology assessment body, has published a final assessment document recommending Beyote ® Zebutinib for the treatment of adult patients with


    NICE's decision marks the ® first and only conventional drug


    WM is a rare B-cell lymphoma that makes up only 2%


    Dr Shirley DSa, Consultant and Clinical Leader of the Centre for Hematology at the WM and Related Diseases Centre at University College London, said: "Beaux-Joy ® is a highly selective BTK inhibitor


    In this evaluation, NICE believes that Baiyueze ® can be regarded as a "significant advance"


    Dr Robert Mulrooney, General Manager of BeiGene, UK and Ireland, said: "I am delighted that NICE has listed NICE ® as an important treatment option for WM patients in England and Wales who meet the treatment standards, which will make WM patients in these areas the first people


    BeiGene has announced that the UK's National Institute for Health and Clinical Excellence (NICE), the UK's health technology assessment body, has published a final assessment document recommending Beyote ® Zebutinib for the treatment of adult patients with


    NICE's decision marks the ® first and only conventional drug


    WM is a rare B-cell lymphoma that makes up only 2%


    Dr Shirley DSa, Consultant and Clinical Leader of the Centre for Hematology at the WM and Related Diseases Centre at University College London, said: "Beaux-Joy ® is a highly selective BTK inhibitor


    In this evaluation, NICE believes that Baiyueze ® can be regarded as a "significant advance"


    Dr Robert Mulrooney, General Manager of BeiGene, UK and Ireland, said: "I am delighted that NICE has listed NICE ® as an important treatment option for WM patients in England and Wales who meet the treatment standards, which will make WM patients in these areas the first people


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.